We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

GELSECTAN®

0

Congresses: Noventure participates at the second edition of IBS Days

Noventure, as part of its ongoing activities in support of the launch of Gelsectan®, participated with a stand at the IBS Days 2018 in Bologne, Italy, May 17 - 19, 2018.   This meeting is intended to provide current views and a look to the future on the rapidly advancing field of IBS. One of the lectures was devoted to mucosal barrier and permeability, which is a hot topic among gastroenterologists specialized in IBS management.  Gelsectan® contains mucoprotectors which improve the resistance of the mucosal barrier and help restore its normal function.  It is intended to relieve and prevent IBS symptoms such as chronic or relapsing diarrhoea, pain and bloating.

Read more

Noventure expands the commercialization of GELSECTAN® across Europe through new partnerships

Noventure is proud to announce new agreements for the distribution of its medical device GELSECTAN® with Klinge (Germany), Tramedico (Benelux), Montavit (Austria), Galenica (Greece, Romania Bulgaria and Cyprus), Lapidot (Israel) and Sabora (Finland). These partnerships come after the successful partnership with Norgine in Spain and Portugal, where GELSECTAN® is already on the market. Irritable bowel syndrome is a burdensome disease which has an estimated global prevalence of more than 10%, predominantly affecting adults, especially women, of working age.

Read more

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Núria Piqué, María del Carmen Gómez-Guillén and María Pilar Montero

Disruption of the epithelial barrier function has been recently associated with a variety of diseases, mainly at intestinal level, but also affecting the respiratory epithelium and other mucosal barriers. Non-pharmacological approaches such as xyloglucan, with demonstrated protective barrier properties, are proposed as new alternatives for the management of a wide range of diseases, for which mucosal disruption and, particularly, tight junction alterations, is a common characteristic.

Read more

Let's meet in..

2018, Oct 09

CPhI

Read more

2018, Oct 24

UEG Week 2018

Read more

2018, Nov 26

EuroPLX 68

Read more

2018, Nov 29

PharmaVenue November 2018

Read more